683 Capital Management, LLC Macrogenics Inc Transaction History

683 Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$7.95 - $12.27 $3.18 Million - $4.91 Million	-400,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$12.44 - $17.48 $1.68 Million - $2.36 Million	-134,970 Reduced 25.23%	400,000 $5.1 Million
Q2 2019 Aug 14, 2019	BUY	$14.51 - $19.71 $725,500 - $985,500	50,000 Added 10.31%	534,970 $9.08 Million
Q1 2019 May 15, 2019	BUY	$11.11 - $25.6 $1.11 Million - $2.56 Million	100,000 Added 25.98%	484,970 $8.72 Million
Q4 2018 Feb 14, 2019	BUY	$11.75 - $21.42 $579,698 - $1.06 Million	49,336 Added 14.7%	384,970 $4.89 Million

Q3 2018 Nov 14, 2018	BUY	$19.26 - $23.46 $1.41 Million - $1.71 Million	73,034 Added 27.81%	335,634 $7.2 Million
Q2 2018 Aug 14, 2018	BUY	$19.78 - $24.67 $249,228 - $310,842	12,600 Added 5.04%	262,600 $5.42 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $4.72 Million - $8.12 Million	250,000 New	250,000 $6.29 Million

111

50M

65.5K

93.9K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $94.6M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.